Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

PF-514273

Bicyclic lactam CB1 antagonist (Ki 1.0 nM), designed by Pfizer for weight management and advanced to clinical trials.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₁H₁₇Cl₂F₂N₃O₂

CAS 851728-60-4

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
452.30 g/mol

Updated on

In plain terms

PF-514273 is a laboratory molecule that blocks the CB1 receptor, the one cannabis activates. Pfizer developed it in 2009 as a drug candidate for weight management and advanced it to trials in humans; it was never marketed. It is now used as a research tool in animals.

Receptors and activity

Target network

CB1AntagonistKi = 1 nM · humanbinding affinity at human CB1 (value read in ChEMBL, Dow 2009); functional antagonism Ki 0.82 nM (CHO-K1, response to CP-55,940)
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to PF-514273: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PF-514273.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1AntagonistKi = 1 nM · human83 out of 100

    Dow et al., J Med Chem 2009: discovery of PF-514273, a bicyclic lactam CB1 receptor antagonist (numerical values read in ChEMBL, document CHEMBL1138462) (new tab) · binding affinity at human CB1 (value read in ChEMBL, Dow 2009); functional antagonism Ki 0.82 nM (CHO-K1, response to CP-55,940)

  2. CB2Binding (function not established)no measured value cited

    Ki greater than 10 000 nM at human CB2 (value read in ChEMBL, Dow 2009): no measurable affinity

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

PF-514273 belongs to the second wave of CB1 receptor antagonists developed for weight management. Dow and colleagues (2009) describe a series of bicyclic lactams, in which molecule 19d, or PF-514273, was selected for its potency and selectivity as a CB1 antagonist and for its oral activity on food intake in rodents; it was advanced to clinical trials in humans. The ChEMBL values for this article give a Ki of 1.0 nM at human CB1 against more than 10,000 nM at CB2, a selectivity of at least 10,000-fold. In rats, oral bioavailability is 42 % and half-life 3.5 hours, with a steady-state brain/plasma ratio of 3.1 (same sources). The context of the class weighed on what followed: rimonabant, authorised in the European Union in June 2006, had its authorisation recommended for suspension by the CHMP on 23 October 2008, with a risk of psychiatric disorders approximately doubled compared with placebo (EMA), and Janero and Makriyannis (2009) report the suspension of the development programmes of rimonabant, taranabant and otenabant. The outcome of the clinical development of PF-514273 is not reported in the sources consulted. The molecule later served as a pharmacological tool (Pina and Cunningham 2014).

History

Source
Entirely synthetic compound with no known natural occurrence. It was produced in a Pfizer pharmaceutical development programme and was not marketed (no marketing authorisation found).

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It is a bicyclic lactam, a 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (name given in the title of Dow et al. 2009).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

PF-514273 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one
Other names
PF 514273 · PF 0514273 · PF514273

Identifiers

Formula
C₂₁H₁₇Cl₂F₂N₃O₂
CAS
851728-60-4
InChIKey
FJMQJSUOOGOWBD-UHFFFAOYSA-N
SMILES
CC(CN1CCOC2=C(N(N=C2C1=O)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl)(F)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.